Olanzapine
Established medicineAlso known as Lybalvi, Symbyax, ZyPREXA, Olanzapin+2 more
Lybalvi, Symbyax, ZyPREXA, Olanzapin, Olanzapina, Olanzapinum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Label change: OLANZAPINE (ANDA219048)
Label change: OLANZAPINE (ANDA077301)
Label change: OLANZAPINE (ANDA210022)
FDA approves Teva’s monthly injection of olanzapine for schizophrenia
<![CDATA[Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia]]>
Label change: OLANZAPINE (ANDA210968)
<![CDATA[Real-World Evidence and Long-Term Data for Lybalvi and Aristada]]>
Psychopharmacological Treatment of Emotional Distress: A Randomized Controlled Trial
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Olanzapine is indicated for the treatment of schizophrenia. Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown… Show full indicationShow less
Olanzapine is indicated for the treatment of schizophrenia. Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Olanzapine is indicated for the treatment of moderate to severe manic episode. In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.
Indication: Adults Olanzapine is indicated for the treatment of schizophrenia. Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have… Show full indicationShow less
Adults Olanzapine is indicated for the treatment of schizophrenia. Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Olanzapine is indicated for the treatment of moderate to severe manic episode. In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.
Indication: Adults Olanzapine is indicated for the treatment of schizophrenia. Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have… Show full indicationShow less
Adults Olanzapine is indicated for the treatment of schizophrenia. Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Olanzapine is indicated for the treatment of moderate to severe manic episode. In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
"Re-examining Maintenance Antipsychotic Treatment in Schizophrenia: "Extended" Antipsychotic Dosing"
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes2
Journals, researchers & institutions
- Anesthesiology1
- Bipolar disorders1
- Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer1
- The American journal of psychiatry1
- The New England journal of medicine1
- Alda M1
- Ascher-Walsh C1
- Barr Grzesh RL1
- Beaulieu S1
- Berk M1
- Blank SV1
- Bond DJ1
- Calabrese JR1
- McMaster University2
- Blavatnik Family Women's Health Research Institute (S.V.B.) Division of Plastic and Reconstructive Surgery1
- Children's Hospital1
- Children's Hospital of Eastern Ontario1
- College of Physicians and Surgeons1
- Connecticut Children's Medical Center1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Acts on the same molecular target as Olanzapine, with 4 overlapping disease areas.
Acts on the same molecular target as Olanzapine, with 3 overlapping disease areas.
Acts on the same molecular target as Olanzapine, with 3 overlapping disease areas.
Studied across 3 of the same disease areas as Olanzapine in the shared literature.
Studied across the same disease area as Olanzapine in the shared literature.
Studied across the same disease area as Olanzapine in the shared literature.
Studied across the same disease area as Olanzapine in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.